We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZGN:NYSEErmenegildo Zegna N.V. Analysis

Data as of 2026-09-01 - not real-time

$13.58

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Ermenegildo Zegna N.V. is bullish at $13.58, with short-term averages leading the long-term ones. Across the trailing 30 sessions it lost 2.3%. With RSI at 42.6 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $13.00 and resistance around $15.95.
On valuation the read is fair — an earnings multiple of 30.9, absent a reliable peer benchmark. The average analyst target implies 10.1% above today's level. The 1.00% dividend yield looks covered by current payout levels.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 30.6%, a beta of 1.30 and a maximum drawdown of 21.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.

Top Market Events

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...Ermenegildo Zegna N.V. NYSE:ZGN the "Company" and, together with its consolidated subsidiaries, the "Ermenegildo Zegna...Seeking Alpha1monErmenegildo Zegna N.V. ZGN Q2 2026 Sales/Trading Call TranscriptGood afternoon, good morning,...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 11.91
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 11.91
  • Analyst targets imply +10.1% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Analyst targets imply +10.1% versus the current price
  • P/E ratio of 30.9
  • Dividend yield of 1.00%

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin5.14%
P/E Ratio30.9
ROE10.52%
ROA3.59%
Debt/Equity89.38
P/B Ratio3.1
Op. Cash Flow$335.6M
Free Cash Flow$246.6M

Technical Analysis

TrendBullish
RSI42.6
Support$13.00
Resistance$15.95
MA 20$14.12
MA 50$13.88
MA 200$11.91
MACDBearish
VolumeStable
Fear & Greed Index94.79

Valuation

Fair Value$9.29
Target Price$14.95
Upside/Downside10.06%
GradeFair
TypeBlend
Dividend Yield1.00%

Risk Assessment

Beta1.30
Volatility30.63%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.